The first Ebola vaccine was approved for circulation

The European Pharmaceutical Commission has approved the circulation of the world's first Ervebo vaccine (rVSV -G-ZEBOV-GP) to prevent Ebola.

The vaccine has been tested on 16,000 people aged 18 and over in clinical studies in Africa, Europe and the United States. The Ervebo vaccine, developed and developed by pharmaceutical firm Merck & Co, has been used effectively in the effort to combat the spread of Ebola in the Congo.

The trial of the Ebola vaccine in Congo began last year, conducted by an international team run by the World Health Organization (WHO).

Earlier, on October 18, WHO praised this achievement in the fight to protect public health. WHO director-general Tedros Adhanom Ghebreyesus said: "This is a vaccine that has saved many lives during the Ebola pandemic. The new EU decision will help more lives be saved."

The EU-approved Ervebo vaccine is circulating to prevent Ebola.(Photo: Reuters)

According to Guido Rasi, President of the European Medicines Agency (CHMP), the Ervebo vaccine, which is licensed for circulation, is an important step forward in the fight against the Ebola epidemic."This is a drug that can address the public health concerns of many countries affected by this pandemic," he said.

The Ebola epidemic killed more than 2,100 people in the world in mid-2018. This is the second largest outbreak in history, after the 2013-2016 epidemic in West Africa that killed more than 11,300 people. Ebola is a rare virus, with extremely serious consequences, impairing liver and kidney function. The death rate in patients is 25-90%. Common symptoms are fever, vomiting, diarrhea, muscle aches and bleeding.

• Ebola vaccine has been 100% effective
• Successfully tested the Ebola vaccine